Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors

被引：0
|
作者：
Dumbrava, Ecaterina Elena
Cecchini, Michael
Zugazagoitia, Jon
Lopez, Juanita Suzanne
Jager, Dirk
Oliva, Marc
Ochsenreither, Sebastian
Gambardella, Valentina
Chung, Ki Y.
Longo, Federico
Razak, Albiruni Ryan Abdul
Wermke, Martin
Evans, T. R. Jeffry
Cook, Natalie
Chenard-Poirier, Maxime
Pencheva, Radost
Schaer, David
Wagener, Thomas
Wagner, Andrea
Papadopoulos, Kyriakos P.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Yale Univ, Sch Med, New Haven, CT USA
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Royal Marsden NHS Trust, Sutton, Surrey, England
[5] NCT Heidelberg, Heidelberg, Germany
[6] Lhosp & Inst Invest Biomed Bellvitge IDIBELL, ICO, Barcelona, Spain
[7] Charite Univ Med Berlin, Berlin, Germany
[8] INCLIVA Biomed Res Inst, Valencia, Spain
[9] Prisma Hlth Canc Inst, Greenville, SC USA
[10] Hosp Univ Ramo y Cajal, Madrid, Spain
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
[12] Tech Univ Dresden, Fac Med, NCT UCC Early Clin Trial Unit, Dresden, Germany
[13] Univ Glasgow, Glasgow, Lanark, Scotland
[14] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[15] Univ Manchester, Manchester, Lancs, England
[16] Univ Laval, CHU Quebec, Quebec City, PQ, Canada
[17] Bayer PLC, Reading, Berks, England
[18] Bayer Healthcare Pharmaceut Inc, Whippany, NJ USA
[19] Bayer AG, Berlin, Germany
[20] START San Antonio, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2502
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors
    Bahleda, R.
    Meric-Bernstam, F.
    Goyal, L.
    Tran, B.
    He, Y.
    Yamamiya, I
    Benhadji, K. A.
    Matos, I
    Arkenau, H-T
    ANNALS OF ONCOLOGY, 2020, 31 (10) : 1405 - 1412
  • [42] First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors
    Tao, Jessica J.
    Cangemi, Nicholas A.
    Makker, Vicky
    Cadoo, Karen A.
    Liu, Joyce F.
    Rasco, Drew W.
    Navarro, Willis H.
    Haqq, Christopher M.
    Hyman, David M.
    CLINICAL CANCER RESEARCH, 2019, 25 (18) : 5458 - 5465
  • [43] Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.
    Voss, Martin Henner
    Hierro, Cinta
    Heist, Rebecca Suk
    Cleary, James M.
    Meric-Bernstam, Funda
    Gandhi, Leena
    Ishii, Nobuya
    Kirpicheva, Yulia
    Nicolas-Metral, Valerie
    Pokorska-Bocci, Anna
    Purcea, Daniela
    Vaslin, Anne
    Moulon, Corinne
    Zanna, Claudio
    Flaherty, Keith
    Tabernero, Josep
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors
    Piha-Paul, Sarina Anne
    Xu, Binghe
    Raghav, Kanwal Pratap Singh
    Meric-Bernstam, Funda
    Janku, Filip
    Dumbrava, Ecaterina Elena
    Fu, Siqing
    Karp, Daniel D.
    Ahnert, Jordi Rodon
    Conley, Anthony Paul
    Mott, Frank
    Ajani, Jaffer A.
    Hong, David S.
    Fan, Ying
    Peng, Peng
    Levin, Wendy J.
    Ngo, Brenda
    Ru, Qinhua Cindy
    Wu, Frank
    Javle, Milind M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
    Herbst, Roy S.
    Kurzrock, Razelle
    Hong, David S.
    Valdivieso, Manuel
    Hsu, Cheng-Pang
    Goyal, Lovely
    Juan, Gloria
    Hwang, Yuying C.
    Wong, Susan
    Hill, John S.
    Friberg, Greg
    LoRusso, Patricia M.
    CLINICAL CANCER RESEARCH, 2010, 16 (23) : 5883 - 5891
  • [46] Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study
    Xu, Jian Ming
    Wang, Yan
    Chen, Yu Ling
    Jia, Ru
    Li, Jie
    Gong, Ji Fang
    Li, Jing
    Qi, Chuan
    Hua, Ye
    Tan, Cui Rong
    Wang, Jian
    Li, Ke
    Sai, Yang
    Zhou, Feng
    Ren, Yong Xin
    Qing, Wei Guo
    Jia, Hong
    Su, Wei Guo
    Shen, Lin
    ONCOTARGET, 2017, 8 (26) : 42076 - 42086
  • [47] First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors
    Do, Khanh T.
    Chow, Laura Quan Man
    Reckamp, Karen
    Sanborn, Rachel E.
    Burris, Howard
    Robert, Francisco
    Camidge, D. Ross
    Steuer, Conor E.
    Strickler, John H.
    Weise, Amy
    Specht, Jennifer M.
    Gutierrez, Martin
    Haughney, Peter
    Hengel, Shawna
    Derleth, Christina Louise
    Yap, Timothy A.
    ONCOLOGIST, 2021, 26 (11): : 925 - +
  • [48] First-in-human phase. study of JPH203 in patients with advanced solid tumors
    Okano, Naohiro
    Kawai, Kirio
    Yamauchi, Yoshiya
    Kobayashi, Takaaki
    Naruge, Daisuke
    Nagashima, Fumio
    Endou, Hitoshi
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [49] A first-in-human phase I study of ER-α36 modifier icaritin in patients with advanced solid tumors.
    Fan, Ying
    Xu, Binghe
    Ding, Xiaoyan
    Ma, Fei
    Wang, Jiayu
    Yuan, Peng
    Luo, Yang
    Li, Qing
    Zhang, Pin
    Cai, Ruigang
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumours
    Yunokawa, M.
    Takahashi, S.
    Aoki, D.
    Yonemori, K.
    Hara, H.
    Hasegawa, K.
    Takehara, K.
    Harano, K.
    Nomura, H.
    Noguchi, E.
    Horie, K.
    Ogasawara, A.
    Okame, S.
    Doi, T.
    ANNALS OF ONCOLOGY, 2019, 30
12345